Cargando…

Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors

Lymphocyte-specific protein tyrosine kinase (LCK) is common in a variety of hematologic malignancies but comparatively less common in solid tumors. This study aimed to explore the potential diagnostic and prognostic value of LCK across tumors through integrative and comprehensive pan-cancer analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Mingwei, Li, Yiming, Guo, Yixiao, Zhu, Wanwan, Jiang, Jianli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697346/
https://www.ncbi.nlm.nih.gov/pubmed/36430477
http://dx.doi.org/10.3390/ijms232213998
_version_ 1784838539440029696
author Han, Mingwei
Li, Yiming
Guo, Yixiao
Zhu, Wanwan
Jiang, Jianli
author_facet Han, Mingwei
Li, Yiming
Guo, Yixiao
Zhu, Wanwan
Jiang, Jianli
author_sort Han, Mingwei
collection PubMed
description Lymphocyte-specific protein tyrosine kinase (LCK) is common in a variety of hematologic malignancies but comparatively less common in solid tumors. This study aimed to explore the potential diagnostic and prognostic value of LCK across tumors through integrative and comprehensive pan-cancer analysis, as well as experimental validation. Multiple databases were used to explore the expression, alteration, prognostic value, association with immune infiltration, and potential functional pathways of LCK in pan-cancers. The results were further validated by western blotting and qPCR of patient samples as well as tumor cell lines. High LCK expression typically represents a better prognosis. Notably, drug sensitivity prediction of LCK identified P-529 as a candidate for drug development. Gene Annotations (GO) and KEGG analyses showed significant enrichment of PD-L1 and the T-cell receptor pathway. The results from patient samples and tumor cell lines confirmed these conclusions in LIHC. In conclusion, LCK is differentially expressed in multiple tumors and normal tissues. Further analysis highlighted its association with prognostic implications, pan-cancer genetic alterations, and immune signatures. Our data provide evidence for a diagnostic marker of LCK and the possible use of LCK as a target for the treatment of tumors.
format Online
Article
Text
id pubmed-9697346
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96973462022-11-26 Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors Han, Mingwei Li, Yiming Guo, Yixiao Zhu, Wanwan Jiang, Jianli Int J Mol Sci Article Lymphocyte-specific protein tyrosine kinase (LCK) is common in a variety of hematologic malignancies but comparatively less common in solid tumors. This study aimed to explore the potential diagnostic and prognostic value of LCK across tumors through integrative and comprehensive pan-cancer analysis, as well as experimental validation. Multiple databases were used to explore the expression, alteration, prognostic value, association with immune infiltration, and potential functional pathways of LCK in pan-cancers. The results were further validated by western blotting and qPCR of patient samples as well as tumor cell lines. High LCK expression typically represents a better prognosis. Notably, drug sensitivity prediction of LCK identified P-529 as a candidate for drug development. Gene Annotations (GO) and KEGG analyses showed significant enrichment of PD-L1 and the T-cell receptor pathway. The results from patient samples and tumor cell lines confirmed these conclusions in LIHC. In conclusion, LCK is differentially expressed in multiple tumors and normal tissues. Further analysis highlighted its association with prognostic implications, pan-cancer genetic alterations, and immune signatures. Our data provide evidence for a diagnostic marker of LCK and the possible use of LCK as a target for the treatment of tumors. MDPI 2022-11-13 /pmc/articles/PMC9697346/ /pubmed/36430477 http://dx.doi.org/10.3390/ijms232213998 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Han, Mingwei
Li, Yiming
Guo, Yixiao
Zhu, Wanwan
Jiang, Jianli
Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title_full Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title_fullStr Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title_full_unstemmed Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title_short Integrative and Comprehensive Pan-Cancer Analysis of Lymphocyte-Specific Protein Tyrosine Kinase in Human Tumors
title_sort integrative and comprehensive pan-cancer analysis of lymphocyte-specific protein tyrosine kinase in human tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697346/
https://www.ncbi.nlm.nih.gov/pubmed/36430477
http://dx.doi.org/10.3390/ijms232213998
work_keys_str_mv AT hanmingwei integrativeandcomprehensivepancanceranalysisoflymphocytespecificproteintyrosinekinaseinhumantumors
AT liyiming integrativeandcomprehensivepancanceranalysisoflymphocytespecificproteintyrosinekinaseinhumantumors
AT guoyixiao integrativeandcomprehensivepancanceranalysisoflymphocytespecificproteintyrosinekinaseinhumantumors
AT zhuwanwan integrativeandcomprehensivepancanceranalysisoflymphocytespecificproteintyrosinekinaseinhumantumors
AT jiangjianli integrativeandcomprehensivepancanceranalysisoflymphocytespecificproteintyrosinekinaseinhumantumors